Relaxin decreases renal interstitial fibrosis and slows progression of renal disease

Relaxin decreases renal interstitial fibrosis and slows progression of renal disease.BackgroundRelaxin, a hormone of the insulin-growth factor family, promotes collagen remodeling. In rodent models of pulmonary and dermal fibrosis, relaxin reduced interstitial fibrosis. To study relaxin's effect in renal disease, we used the experimental bromoethylamine (BEA) model that leads to severe renal interstitial fibrosis, a decrease in glomerular filtration rate, and albuminuria at one month.MethodsRats were injected with BEA one week prior to implantation of an osmotic pump delivering relaxin (2 μg/hour) or vehicle continuously for 28 days.ResultsBEA caused a significant decrease in creatinine clearance, which was partially prevented by relaxin. In the relaxin-treated BEA rats, serum creatinine was normal, and albumin excretion was slightly decreased. By morphometric measurement, relaxin administration was associated with a significant decrease in interstitial fibrosis at the corticomedullary junction. This was accompanied by a decrease in the number of ED-1 positive cells (an index of macrophage infiltration) and in the intensity of immunohistochemical staining for transforming growth factor-β. This antifibrotic effect of relaxin did not appear to be mediated by systemic hemodynamic changes since the mean arterial pressure was not significantly different among the groups.ConclusionsRelaxin may have a useful application in decreasing interstitial fibrosis and thereby slowing the progression of renal disease